Illegal Manipulation of Your Body
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Case – Tdf Diagnostic Hypotheses 2013
____________________ ____________________ ____________________ ____________________ ____________________ ____________________ ____________________ ____________________ ____________________ ____________________ ____________________ ____________________ Froome's performances since the Vuelta 11 are so good that he should be considered a Grand Tour champion. Grand Tour champions who didn't benefit from game-changing drugs (GTC) usually display a high potential as junior athletes. Supporting evidence: Coppi first won the Giro at 20 Anquetil first won the Grand Prix des Nations at 19 Merckx won the world's road at 19 Hinault won the Giro and Tour at 24 LeMond showed amazing talent at just 15 Fignon led the Giro and won the Critèrium national at 22 No display of early talent H: Froome rode the 2013 TdF 'clean' ~H: Froome didn't ride the 2013 TdF 'clean' Reason: Because p(D|H) = Objection: But that's because he grew up in Evaluation Froome didn't display a high Froome's first major wins a country with no cycling activity per say and p(D|~H) = potential as a junior athlete. were at age 26, which is he took up road racing late. quite late in cycling. Cognitive dissonance (additional condition): Being clean, Froome performs at a Grand Tour champion level despite not having shown great potential as a junior athlete. Requirement: it is possible to be a clean Grand Tour champion without showing high potential as a junior athlete. Armstrong's performance in the TdF: DNF, DNF, 36, DNF, DNS [cancer], DNS [cancer], 1, 1, 1, 1, 1, 1, 1, 3, 23 Sudden metamorphoses from 'middle of the pack' to 'champion' are Team Sky's director Brailsford: "We also look at the history of the guy, his usually seen in dopers. -
Dates of Affidavits Incredibly, All but One of the Affidavits Cited by USADA Were Signed in September and October of This Year
Dates of Affidavits Incredibly, all but one of the affidavits cited by USADA were signed in September and October of this year. This list: Frankie Andrue: 9/24/12 Michael Barry: 10/8/12 Leonardo Bertagnolli: (unknown) Volodymyr Bileka: 11/10/10 Tom Danielson: 9/26/12 Tyler Hamilton: 9/28/12 George Hincapie: 9/24/12 Jorg Jaksche: 10/4/12 Floyd Landis: 9/26/12 Levi Leipheimer: 9/21/12 Filippo Simeoni: 9/10/12 or 10/9/12 Stephen Swart: 9/17/12 Christian Vande Velde: 9/25/12 Jonathan Vaughters: 9/12/12 David Zabriski: 9/4/12 (notary states 10/4/12) Betsy Andreu: 9/21/12 Piero Boccarossa: 9/25/12 Larry Bowers: 10/8/12 Marco Consonni: 10/4/12 Renzo Ferrante: 9/27/12 Emma O’Reilly: 10/9/12 Dawn Polay: 9/26/12 Jack Robertson: 10/9/12 Paul Scott: 10/9/12 Lory Testasecca: 9/23/12 Jean-Pierre Verdy: 9/10/12 Why is this incredible? For two reasons: First, all of the key witnesses in this case only swore under oath AFTER they knew that Armstrong was not contesting the USADA allegations (a decision announced on August 24, 2012). In other words, not a single key witness was willing to swear under oath until they were absolutely sure that there would be no adversarial proceeding, until they were absolutely sure that they would not be subject to cross examination, and until they were absolutely sure that their testimony would not be impeached by third parties or by special deals that the witnesses had made with USADA. -
Olympic Doping
Even some Olympic athletes cheat with drugs | Science News for Students 3/16/20, 6:42 AM HEALTH & MEDICINE Even some Olympic athletes cheat with drugs As new ways of doping emerge, scientists develop ways to catch the cheaters Athletes train to get stronger, run faster and jump higher. But some may turn to an illegal short-cut: performance-enhancing drugs. Scientists are working to find these cheaters. JACOB AMMENTORP LUND/ISTOCKPHOTO By Sarah Zielinski August 15, 2016 at 6:00 am MANCHESTER, England — Keen viewers of the Rio Olympics this week may notice that one country’s team is a lot smaller than usual. Russia brought only about 70 percent of the athletes it had expected would compete. Some 30 percent — including all weightlifters and all but one track and field athletes — were banned from the competition. The reason? They were caught up in a cheating scandal. The type of cheating these athletes had participated in is known as “doping.” It involves the use of drugs to improve performance. These drugs have medical purposes for people who are ill. But in healthy athletes, they can provide an illegal advantage by boosting muscle growth or offering other benefits. And it’s not just using these substances that can get an athlete in trouble. Athletes also can get banned for refusing to participate in (or tampering with) efforts to find others who use doping drugs. The Russian scandal involved an elaborate plot to https://www.sciencenewsforstudents.org/article/even-some-olympic-athletes-cheat-drugs Page 1 of 5 Even some Olympic athletes cheat with drugs | Science News for Students 3/16/20, 6:42 AM interfere with these tests. -
United States District Court Western District of Texas Austin Division
UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION Lance Armstrong Plaintiff, v. Civ. Action No. ______. United States Anti-Doping Agency and Travis Tygart, in his official capacity as Chief Executive Officer of the United States Anti-Doping Agency Defendants. COMPLAINT AND JURY DEMAND Comes now, Plaintiff Lance Armstrong, by his undersigned counsel, and states and alleges as follows: Parties 1. Plaintiff Lance Armstrong, 300 West 6th Street, Suite 2150 Austin, Texas, is a citizen of Travis County, Texas. He resides in Austin, Texas. 2. Defendant United States Anti-Doping Agency (―USADA‖) is a Colorado Corporation with its principal place of business at 5555 Tech Center Drive, Suite 200, Colorado Springs, Colorado 80919. USADA is the national anti-doping organization for the United States and manages the United States‘ anti-doping testing program for National Governing Bodies for Olympic, Paralympic, and Pan-American Games Sports. 3. Defendant Travis Tygart is a resident of the state of Colorado. Mr. Tygart is named as a Defendant in his official capacity as the Chief Executive Officer (―CEO‖) of USADA, with his principal place of business at 5555 Tech Center Drive, Suite 200, Colorado Springs, Colorado 80919. Nature of Action 4. Mr. Armstrong brings this Complaint against USADA and its CEO, Travis Tygart, to prevent imminent violations of Mr. Armstrong‘s Constitutional and common law due process rights, by which the Defendants would strip Mr. Armstrong of his livelihood, his seven Tour de France titles, and the many other honors he has won in his world-renowned cycling career. 5. Defendants‘ actions demonstrate their belief that USADA is above the United States Constitution, above the law, above court review, free from supervision from any person or organization, and even above its own rules. -
Gene… Sport Science 14 (2020) Suppl 1: 18-23
Mazzeo, F., et al.: New technology and no drugs in sport: gene… Sport Science 14 (2020) Suppl 1: 18-23 NEW TECHNOLOGY AND NO DRUGS IN SPORT: GENE DOPING REGULATION, EDUCATION AND RESEARCH Filomena Mazzeo1 and Antonio Ascione2 1Department of Sport Sciences and Wellness, Parthenope University, Naples, Italy 2University of Bari “Aldo Moro”, Italy Review paper Abstract This article examines the current state of genetic doping, the use of gene therapy in sports medicine, and the ethics of genetic improvement. The purpose of gene therapy is to use the foundations of genetic engineering for therapeutic use. Gene doping is a expansion of gene therapy. Innovative research in genetics and genomics will be used not only to diagnose and treat disease, but also to increase endurance and muscle mass. The first genetic therapy tests were conducted with proteins closely related to doping (e.g. erythropoietin and growth hormone). The World Anti-Doping Agency (WADA), an international organization created in 1999 to "promote, coordinate, and monitor the fight against doping in sport in all its forms," defines gene doping as the "nontherapeutic use of cells, genes, genetic elements, or modulation of gene expression, having the capacity to enhance performance" (World Anti-Doping Agency, 2008). This method represents a new Technology, but not devoid of adverse and fatal effects; gene doping could be dangerous for the athlete. The use of the athlete's biological-molecular passport represents a possible preventive and precautionary anti-doping strategy. The best way to prevent gene doping is a combination of regulation, education, research and the known of health risks. -
Fans Don't Boo Nobodies: Image Repair Strategies of High-Profile Baseball Players During the Steroid Era
Brigham Young University BYU ScholarsArchive Theses and Dissertations 2011-09-23 Fans Don't Boo Nobodies: Image Repair Strategies of High-Profile Baseball Players During the Steroid Era Kevin R. Nielsen Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Communication Commons BYU ScholarsArchive Citation Nielsen, Kevin R., "Fans Don't Boo Nobodies: Image Repair Strategies of High-Profile Baseball Players During the Steroid Era" (2011). Theses and Dissertations. 2876. https://scholarsarchive.byu.edu/etd/2876 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Fans don't boo nobodies: Image repair strategies of high-profile baseball players during the Steroid Era Kevin Nielsen A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Arts Steve Thomsen, Chair Kenneth Plowman Tom Robinson Department of Communications Brigham Young University December 2011 Copyright © 2011 Kevin Nielsen All Rights Reserved Fans don't boo nobodies: Image repair strategies of high-profile baseball players during the Steroid Era Kevin Nielsen Department of Communications, BYU Master of Arts Baseball's Steroid Era put many different high-profile athletes under pressure to explain steroid allegations that were made against them. This thesis used textual analysis of news reports and media portrayals of the athletes, along with analysis of their image repair strategies to combat those allegations, to determine how successful the athletes were in changing public opinion as evidenced through the media. -
The Tour De France, Lance Armstrong, and the Rumors of Drugs
University of Central Florida STARS On Sport and Society Public History 7-28-2003 The Tour de France, Lance Armstrong, and the rumors of drugs Richard C. Crepeau University of Central Florida, [email protected] Part of the Cultural History Commons, Journalism Studies Commons, Other History Commons, Sports Management Commons, and the Sports Studies Commons Find similar works at: https://stars.library.ucf.edu/onsportandsociety University of Central Florida Libraries http://library.ucf.edu This Commentary is brought to you for free and open access by the Public History at STARS. It has been accepted for inclusion in On Sport and Society by an authorized administrator of STARS. For more information, please contact [email protected]. Recommended Citation Crepeau, Richard C., "The Tour de France, Lance Armstrong, and the rumors of drugs" (2003). On Sport and Society. 546. https://stars.library.ucf.edu/onsportandsociety/546 SPORT AND SOCIETY FOR H-ARETE July 28, 2003 Lance Armstrong once called the Tour de France "a contest in purposeless suffering." In a different mood Armstrong dubbed the Tour as "the most gallant athletic endeavor in the world." He may well have been right on both occasions. The Tour de France was created by Henri Desgrange who was looking for a way to promote his cycling newspaper, L'Auto. In the first year it was a simple six-stage loop of 2,428 kilometers around France. Riders worked alone with no crew or assistants to help them along the way. In 1906, to add to the challenge, a stage was added into the Pyrenees. -
Landis Admits Doping, Alleges Armstrong
WSJ: Cyclist Floyd Landis Admits Doping, Alleges Use by Armstrong and Others By Reed Albergotti and Vanessa O'Connell Of THE WALL STREET JOURNAL 833 words 20 May 2010 01:27 Dow Jones International News DJI English (c) 2010 Dow Jones & Company, Inc. Floyd Landis, the American cyclist whose 2006 Tour De France victory was nullified after a positive doping test, has sent a series of emails to cycling officials and sponsors admitting to, and detailing, his systematic use of performance enhancing drugs during his career. The emails also claim that other riders and cycling officials allegedly participated in doping, including seven-time Tour de France winner Lance Armstrong. It's unclear how many emails Mr. Landis sent. Three emails, which are dated between April 30 and May 6, have been reviewed by The Wall Street Journal. Mr. Landis copied seven people on these three emails, including officials with USA Cycling and the International Cycling Union. Three people who have seen the emails and spoken to Mr. Landis about them say they are authentic. Mr. Armstrong did not respond to messages seeking comment Wednesday evening. Mr. Armstrong has faced a number of doping accusations during his career, which he has denied. He has never been sanctioned. Mr. Landis's charges couldn't be independently verified. Mr. Landis did not respond to a request for comment. In the emails, he expressed frustration about the inability of antidoping officials to clean up the sport. After the Tour De France stripped Mr. Landis of his 2006 victory for testing positive for elevated levels of testosterone after one crucial stage of the race, the U.S. -
Development of Doping in Sports: Overview and Analysis
Journal of Physical Education and Sport ® (JPES), 18(3), Art 244, pp. 1669 - 1677, 2018 online ISSN: 2247 - 806X; p-ISSN: 2247 – 8051; ISSN - L = 2247 - 8051 © JPES Original Article Development of Doping in sports: overview and analysis FILOMENA MAZZEO1, GAETANO ALTAVILLA2, FRANCESCA D’ELIA3, GAETANO RAIOLA3 1Department of Science and Technology University of Naples “Parthenope”, Naples, ITALY 2Faculty of Kinesiology, University of Split, Split CROATIA 3Department of Human Philosophical and Education sciences, University of Salerno, ITALY Published online: September 30, 2018 (Accepted for publication August 10, 2018) DOI:10.7752/jpes.2018.03244 Abstract: Doping is a public health issue and not simply a problem inside the professional sports community It is a complex and ancient phenomenon considering the vast variety of substances, supplied through both legal and illegal trading routes. It occurs in elite athletes but also affects amateur athletes and was generally considered as dangerous and unhealthy. Furthermore, it involves athletes’ friends and relatives, medical staff, managers, chemists, biologists and pharmacists, pharmaceutical industries, clandestine laboratories and criminal organizations. Over time, doping has shown a great ability to discover and always use new substances and appropriated the new scientific discoveries. Unfortunately, new discoveries for the human health are been used in distorted way by the athletes. In fact, the athletes may be able to use gene therapy to re-engineer their bodies for better performances. Drug dependence depends on several factors: the socio-environmental context of the subject and what effects have the substance in the body. We will agree that sport is essentially under the current anti-doping campaign executed by a coordinated alliance between the World Anti-Doping Agency (WADA), law enforcement authorities, sports organizers and the media. -
PUBLIC ASSESSMENT REPORT Decentralised Procedure Dienogest
PUBLIC ASSESSMENT REPORT Decentralised Procedure Dienogest Aristo 2 mg Tabletten Procedure Number: DE/H/5431/001/DC Active Substance: Dienogest Dosage Form: Tablet Marketing Authorisation Holder in the RMS, Germany: Aristo Pharma GmbH Publication: 18.12.2019 This module reflects the scientific discussion for the approval of Dienogest Aristo 2 mg Tabletten. The procedure was finalised on 10.10.2019. TABLE OF CONTENTS I INTRODUCTION ......................................................................................................................... 4 II EXECUTIVE SUMMARY .......................................................................................................... 4 II.1 PROBLEM STATEMENT............................................................................................................... 4 II.2 ABOUT THE PRODUCT ................................................................................................................ 4 II.3 GENERAL COMMENTS ON THE SUBMITTED DOSSIER ............................................................... 5 II.4 GENERAL COMMENTS ON COMPLIANCE WITH GMP, GLP, GCP AND AGREED ETHICAL PRINCIPLES ........................................................................................................................................... 5 III SCIENTIFIC OVERVIEW AND DISCUSSION .................................................................... 6 III.1 QUALITY ASPECTS .................................................................................................................... 6 III.2 -
Gene Doping Detection Based on Polymerase Chain Reaction (PCR)
Laboratory Guidelines Gene Doping Detection based on Polymerase Chain Reaction (PCR) Version 1.0 January 2021 TABLE OF CONTENTS 1.0 Objective ......................................................................................................................... 3 2.0 Scope .............................................................................................................................. 3 3.0 Introduction .................................................................................................................... 3 4.0 Test Requirements ........................................................................................................ 3 4.1. Test Method Validation Requirements ..................................................................................... 3 4.2. Test Method Accreditation Requirements ................................................................................ 4 4.3. Pre-analytical Procedure ......................................................................................................... 4 4.4. Analytical Testing Procedure ................................................................................................... 5 4.4.1. Initial Testing Procedure (ITP) .......................................................................................... 5 4.4.2. Confirmation Procedures (CPs) ........................................................................................ 6 5.0 Interpretation and Reporting of Results ..................................................................... -
Zij Blijven Allemaal Goden
Zij blijven allemaal goden Zij blijven allemaal goden Een waarheidsgetrouwe reconstructie van een fictieve Ronde van Frankrijk Jeen de Jong Brave New Books Eerste druk, juni 2021 © Jeen de Jong Omslagfoto: Chloé Leclerq ISBN 9789464353525 NUR 489 bravenewbooks.nl/jeendejong1 ‘De mensen kunnen de goden niet missen.’ ~ Homerus ‘Toen ik de beroemde vragenlijst van Marcel Proust kreeg voorgelegd en ik moest zeggen wat ik het liefste deed, antwoordde ik tot de gepaste verbazing van de literaire gemeenschap: ‘De Tour de France volgen.’’ ~ Antoine Blondin ‘Een dichter moet sporen achterlaten, geen bewijzen. Alleen sporen wekken dromen op.’ ~ René Char Inhoudsopgave Rittenschema ...........................................................................................................................................................7 Deelnemerslijst ........................................................................................................................................................8 1. Vrijdag 30 juni | Ploegenpresentatie | Parc des Princes, Parijs.........................................................................11 2. Zaterdag 1 juli | Proloog | Parijs – Parijs | 7.2 kilometer ..................................................................................20 3. Zondag 2 juli | Etappe 1 | Parijs – Arras | 290.3 kilometer ...............................................................................25 4. Maandag 3 juli | Etappe 2 | Arras - Roubaix | 170.3 kilometer ........................................................................31